Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine
This page shows you your search results in order of relevance. This is page number 18.
Order by Relevance | Date
Total 1783 results found since Jan 2013.
An Orally Administered Nonpathogenic Attenuated Vaccine Virus Can Be Used to Control SARS-CoV-2 Infection: A Complementary Plan B to COVID-19 Vaccination
Conclusions SIT has already been demonstrated to be safe and effective against five different families of viruses, hepatitis A virus, hepatitis B virus, hepatitis C virus, SARS-CoV-2, and herpes zoster virus. The R903/78 drug candidate is simple to manufacture and easy to administer in an outpatient setting. The expected cost of SIT will be affordable even in resource-limited countries.PMID:36176842 | PMC:PMC9511982 | DOI:10.7759/cureus.28467
Source: Herpes - September 30, 2022 Category: Infectious Diseases Authors: Tibor Bakacs Volker Sandig Imre Kovesdi Source Type: research
The Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Slovenia
Conclusion: Policymakers should consider implementing UVV to reduce the burden of varicella disease in Slovenia.PMID:36196453 | PMC:PMC9489276 | DOI:10.36469/001c.37308
Source: Herpes - October 5, 2022 Category: Infectious Diseases Authors: Colleen Burgess Stephanie Kujawski Ajda Lapornik Goran Bencina Manjiri Pawaskar Source Type: research
A Case of Herpes Zoster Due to Varicella-Zoster Virus Vaccines in a 14-Month-old Girl
We report a case of HZ due to VZV vaccines presented in an immunocompetent 14-month-old girl 62 days after vaccination which is the youngest case from the first dose of the VZV vaccine in immunocompetent children.PMID:36197397 | PMC:PMC9508941 | DOI:10.1097/INF.0000000000003638
Source: Herpes - October 5, 2022 Category: Infectious Diseases Authors: Tatsuo Koide Toshinori Nishigaki Source Type: research
The Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Slovenia
Conclusion: Policymakers should consider implementing UVV to reduce the burden of varicella disease in Slovenia.PMID:36196453 | PMC:PMC9489276 | DOI:10.36469/001c.37308
Source: Herpes - October 5, 2022 Category: Infectious Diseases Authors: Colleen Burgess Stephanie Kujawski Ajda Lapornik Goran Bencina Manjiri Pawaskar Source Type: research
Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
Open Forum Infect Dis. 2022 Oct 23;9(10):ofac485. doi: 10.1093/ofid/ofac485. eCollection 2022 Oct.ABSTRACTApproximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.PMID:36299530 | PMC:PMC9588150 | DOI:10.1093/ofid/ofac485
Source: Herpes - October 27, 2022 Category: Infectious Diseases Authors: Ana Strezova Javier Diez-Domingo Kamal Al Shawafi Juan Carlos Tinoco Meng Shi Paola Pirrotta Agnes Mwakingwe-Omari Zoster-049 Study Group Source Type: research
Examples of Outcome Reporting Bias in Vaccine Studies: Illustrating How Perpetuating Medical Consensus Can Impede Progress in Public Health
CONCLUSIONS: Conflicts of interest (e.g., financial) that abound between health regulatory agencies and the pharmaceutical industry impact what is ultimately reckoned as medical consensus. Outcome reporting bias that is inherent to all researchers to some degree, obscures medical and scientific truth. Advancement of public health requires that researchers have integrity and an openness and willingness to collaborate to resolve contradictory findings. In fact, it is usually through meticulous, rigorous, scientific investigation of contradictory findings that medical science has advanced and contributed to improvements in pu...
Source: Herpes - October 28, 2022 Category: Infectious Diseases Authors: Gary S Goldman Source Type: research
Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
Open Forum Infect Dis. 2022 Oct 23;9(10):ofac485. doi: 10.1093/ofid/ofac485. eCollection 2022 Oct.ABSTRACTApproximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.PMID:36299530 | PMC:PMC9588150 | DOI:10.1093/ofid/ofac485
Source: Herpes - October 27, 2022 Category: Infectious Diseases Authors: Ana Strezova Javier Diez-Domingo Kamal Al Shawafi Juan Carlos Tinoco Meng Shi Paola Pirrotta Agnes Mwakingwe-Omari Zoster-049 Study Group Source Type: research
Examples of Outcome Reporting Bias in Vaccine Studies: Illustrating How Perpetuating Medical Consensus Can Impede Progress in Public Health
CONCLUSIONS: Conflicts of interest (e.g., financial) that abound between health regulatory agencies and the pharmaceutical industry impact what is ultimately reckoned as medical consensus. Outcome reporting bias that is inherent to all researchers to some degree, obscures medical and scientific truth. Advancement of public health requires that researchers have integrity and an openness and willingness to collaborate to resolve contradictory findings. In fact, it is usually through meticulous, rigorous, scientific investigation of contradictory findings that medical science has advanced and contributed to improvements in pu...
Source: Herpes - October 28, 2022 Category: Infectious Diseases Authors: Gary S Goldman Source Type: research
Trigeminal neuropathy after tozinameran vaccination against COVID-19 in postmicrovascular decompression for trigeminal neuralgia: illustrative case
J Neurosurg Case Lessons. 2022 Apr 18;3(16):CASE22101. doi: 10.3171/CASE22101. Print 2022 Apr 18.ABSTRACTBACKGROUND: Vaccines against coronavirus disease 2019 have a high level of efficacy and safety across all populations. However, numerous case series have been published on neurological disorders, including Bell's palsy, Guillain-Barre syndrome, transverse myelitis, and multiple sclerosis. The authors presented a case of trigeminal neuropathy after coronavirus vaccination in a patient who had undergone microvascular decompression (MVD) for trigeminal neuralgia (TN).OBSERVATIONS: A 77-year-old woman presented with acute t...
Source: Herpes - October 28, 2022 Category: Infectious Diseases Authors: Keisuke Onoda Ryohei Sashida Ren Fujiwara Tomihiro Wakamiya Yuhei Michiwaki Tatsuya Tanaka Kazuaki Shimoji Eiichi Suehiro Fumitaka Yamane Masatou Kawashima Akira Matsuno Source Type: research
The Awareness and Attitude of Physicians to Older Adult Routine Vaccination Scheme
CONCLUSION: Awareness of routine vaccination schedules should be improved among health-care professionals, and reminders for immunization should be provided periodically in each health-care setting.PMID:36338873 | PMC:PMC9635550 | DOI:10.2147/CIA.S382311
Source: Herpes - November 7, 2022 Category: Infectious Diseases Authors: Esra Ates Bulut Suade Ozlem Badak Huseyin Aksoy Ayse Fadiloglu Ahmet Turan Isik Source Type: research
Safety of mRNA COVID-19 Vaccines in Patients with Inborn Errors of Immunity: an Italian Multicentric Study
CONCLUSION: Although our follow-up period is relatively short, the safety data we reported are reassuring. This data would help to contrast the vaccine hesitancy often manifested by patients with IEI and to better inform their healthcare providers.PMID:36374363 | PMC:PMC9662105 | DOI:10.1007/s10875-022-01402-6
Source: Herpes - November 14, 2022 Category: Infectious Diseases Authors: Cinzia Milito Francesco Cinetto Giulia Garzi Andrea Palladino Marco Puca Elena Brambilla Camilla De Vitis Giulia Costanzo Riccardo Scarpa Alessandra Punziano Gianluca Lagnese Stefano Del Giacco Giuseppe Spadaro Isabella Quinti Davide Firinu Source Type: research
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
Viruses. 2022 Nov 29;14(12):2667. doi: 10.3390/v14122667.ABSTRACTInfection with varicella zoster virus typically occurs in children and it can cause primary varicella infection or "chickenpox", or it can reactivate later in life and cause herpes zoster or "shingles". Herpes zoster mainly occurs in older adults, causing a reduction in activities of daily living, impacting quality of life, and may lead to serious complications, including chronic pain. Two vaccines are marketed to prevent herpes zoster: the live zoster vaccine and the non-live, recombinant zoster vaccine. The pre-licensure clinical trials show the efficacy of...
Source: Herpes - December 23, 2022 Category: Infectious Diseases Authors: Yasmin Marra Fawziah Lalji Source Type: research
